Bassil Dahiyat | BiotechTV

top of page

Search

Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise

Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise

Barclays Miami: Xencor CEO Bassil Dahiyat discusses the company's internal pipeline and how bi-specifics and other modalities are engineered to be increasingly sophisticated and more precise

He highlights pipeline programs targeting ENPP3, CLDN6, CLDN18.2, TL1A (including TL1A x IL23p19), CD20 x CD3, and CD19xCD3.

4 hours ago

Five Questions with Xencor CEO Bassil Dahiyat

Five Questions with Xencor CEO Bassil Dahiyat

Five Questions with Xencor CEO Bassil Dahiyat

Bassil Dahiyat walks us through the latest advances in bi-specific antibody engineering and gives his take on L.A.'s biotech scene.

Feb 2, 2024

Modality profile: Bi-Specifics and cytokines at #ASCO23

Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.

Jun 3, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page